Small molecule drug research and development is still the main battlefield for new drug research and development

Compared with biomacromolecule drugs, small molecule drugs have greater advantages in R&D cost and process maturity.
Therefore, in the field of pharmaceutical R&D, small molecule R&D is a topic that cannot be avoided, and it is still the research and development of new drugs.
The main battlefield
.
According to statistics, the sales of well-sold small molecule drugs are close to 15 billion U.
S.
dollars; 88 small molecule drugs have sales of more than 1 billion U.
S.
dollars; the sales ranking of 200 small molecule drugs is about 335 million U.
S.
dollars.
.
.
Analysts said that the small molecule drug market is still large, and it is still worthwhile for most domestic pharmaceutical companies
.
The author has learned that in the small molecule drug market, many domestic companies are still stepping up their deployment
.
For example, Anrui Bio is a company focusing on the development of next-generation precision medicine small molecule new drugs for the treatment of tumors and autoimmune diseases.
Limited to covalent and allosteric small molecules
.
On November 23 news, Anrui Biomedicine announced that it has completed a US$40 million Series A financing.
This round of financing will be used for the preclinical research and Sino-US IND declarations of Anrui's multiple small molecule new drug projects, and continue to improve and strengthen the transformation.
Systematic screening of inhibitors and verification of targets for synthetic lethal mechanisms and small molecule discovery platforms
.
On November 19th, Yinming Biotechnology announced that its first-in-class tumor immune target HPK1 small molecule inhibitor PRJ1-3024 had passed the US FDA's IND program and officially launched a phase I clinical trial in the United States
.
PRJ1-3024 passed the clinical application process in the United States, marking Yinming's official participation in the competition of the 100 billion-dollar track of innovative tumor immune drugs
.
It is reported that HPK1 is an important target in tumor immunity
.
Targeting HPK1 can effectively regulate several types of important immune cells and activate their synergistic anti-tumor effects
.
Yinming has a solid scientific foundation on the target mechanism of HPK1
.
PRJ1-3024 is a product independently developed by Yinming Biotech.
It is in the first echelon of the world and has a series of advantages such as better selectivity.

.
In addition, Haoyuan Pharmaceutical has vividly interpreted the great achievements of small molecules with 15 years of development
.
It is reported that since its establishment in 2006, Haoyuan Pharmaceutical has been committed to the research and development of small molecules with high technical barriers, difficulty, and high technical added value.
With its technical advantages in medicinal chemistry and organic synthesis, it has responded quickly to meet the needs of multinational pharmaceutical companies.
Companies, scientific research institutes and universities need to use various advanced and cutting-edge laboratory chemical synthesis technologies to provide complex molecular building blocks and tool compounds, high-end pharmaceutical raw materials and intermediates for the research and development needs of compound design and synthesis in the drug discovery stage.
Custom synthesis
.
Analysts pointed out that with China's continuous emphasis on innovative drug R&D and increased investment, independent drug R&D has gradually become a goal pursued by major pharmaceutical companies and scientific research institutions
.
The independent research and development of innovative small-molecule chemical drugs requires deep accumulation of basic research, a large amount of capital investment and innovative research methods, which are often the vane in new drug research
.
It is reported that in the field of small molecule chemical innovation drug research and development, there have been new achievements in recent years
.
For example, it is suitable for Sofantinib for non-pancreatic neuroendocrine tumors that cannot be surgically removed or metastatic, advanced non-functional, and well-differentiated (G1, G2) non-pancreatic neuroendocrine tumors, combined with sofosbuvir, suitable for Emitavir phosphate (Dongweien) for the treatment of adult genotype 1 non-cirrhotic chronic hepatitis C; used for platinum-sensitive recurrent ovarian cancer with germline BRCA mutation (gBRCAm) that has undergone second-line and above chemotherapy, Fluzoparil (Irei) and other small-molecule chemical drugs for the treatment of patients with fallopian tube cancer or primary peritoneal cancer were approved in 2020
.
It is understood that with the rapid development of molecular biology and structural biology, small molecule drug discovery has entered the era of target-based drug design.
At the same time, many new technologies and new methods have emerged in the field of small molecules, such as PROTAC and molecular glue.
Kind of protein degradation therapy
.
In the future, with the help of artificial intelligence technology, small molecule drugs will usher in an opportunity to flourish
.
According to the industry, with the increasing abundance and maturity of new technologies, small molecule drugs will bring new hope to unresolved clinical needs
.
window.
_bd_share_config={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"32"},"share":{},"image":{"viewList":["weixin","sqq","qzone","tsina","tqq"," tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:", "viewSize":"24"},"selectShare":{"bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu", "tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}};with(document)0[(getElementsByTagName('head ')[0]||body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js ?cdnversion='+~(-new Date()/36e5)]; Keywords: Small molecule drug research and development is still the main battlefield of new drug research and development, small molecule drugs Next: After entering centralized procurement and medical insurance, multinational pharmaceutical companies How is the product sales performance? Previous post: Mindray Anhui Collective: Performance is expected to double, ushering in a large number of foreign dealers to switch to.
.
.
[Information search] [Add to Favorites] [Tell friends] [Print this article] [Close window] Similar information js?cdnversion='+~(-new Date()/36e5)]; Keywords: Small molecule drug research and development is still the main battlefield of new drug research and development, small molecule drugs Next: After entering centralized procurement and medical insurance, transnational drugs How is the sales performance of the company's products? Previous post: Mindray Anhui Collective: Performance is expected to double, ushering in a large number of foreign dealers to switch to.
.
.
[Information search] [Add to Favorites] [Tell friends] [Print this article] [Close window] Similar information js?cdnversion='+~(-new Date()/36e5)]; Keywords: Small molecule drug research and development is still the main battlefield of new drug research and development, small molecule drugs Next: After entering centralized procurement and medical insurance, transnational drugs How is the sales performance of the company's products? Previous post: Mindray Anhui Collection: Performance is expected to double, ushering in a large number of foreign dealers to switch to.
.
.
[Information Search] [Add to Favorites] [Tell a Friend] [Print this article] [Close Window] Similar information